650 related articles for article (PubMed ID: 31295065)
1. Nutraceutical and pharmaceutical cocktails did not improve muscle function or reduce histological damage in D2-mdx mice.
Spaulding HR; Quindry T; Hammer K; Quindry JC; Selsby JT
J Appl Physiol (1985); 2019 Oct; 127(4):1058-1066. PubMed ID: 31295065
[TBL] [Abstract][Full Text] [Related]
2. Nutraceutical and pharmaceutical cocktails did not preserve diaphragm muscle function or reduce muscle damage in D2-mdx mice.
Spaulding HR; Quindry T; Quindry JC; Selsby JT
Exp Physiol; 2020 Jun; 105(6):989-999. PubMed ID: 32267561
[TBL] [Abstract][Full Text] [Related]
3. Oral quercetin administration transiently protects respiratory function in dystrophin-deficient mice.
Selsby JT; Ballmann CG; Spaulding HR; Ross JW; Quindry JC
J Physiol; 2016 Oct; 594(20):6037-6053. PubMed ID: 27094343
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Quercetin Dietary Enrichment Partially Protects Dystrophic Skeletal Muscle.
Spaulding HR; Ballmann CG; Quindry JC; Selsby JT
PLoS One; 2016; 11(12):e0168293. PubMed ID: 27977770
[TBL] [Abstract][Full Text] [Related]
5. Long-term quercetin dietary enrichment decreases muscle injury in mdx mice.
Hollinger K; Shanely RA; Quindry JC; Selsby JT
Clin Nutr; 2015 Jun; 34(3):515-22. PubMed ID: 24998094
[TBL] [Abstract][Full Text] [Related]
6. Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy.
Janssen PM; Murray JD; Schill KE; Rastogi N; Schultz EJ; Tran T; Raman SV; Rafael-Fortney JA
PLoS One; 2014; 9(2):e88360. PubMed ID: 24551095
[TBL] [Abstract][Full Text] [Related]
7. Long-term dietary quercetin enrichment as a cardioprotective countermeasure in mdx mice.
Ballmann C; Denney T; Beyers RJ; Quindry T; Romero M; Selsby JT; Quindry JC
Exp Physiol; 2017 Jun; 102(6):635-649. PubMed ID: 28192862
[TBL] [Abstract][Full Text] [Related]
8. Lifelong quercetin enrichment and cardioprotection in Mdx/Utrn+/- mice.
Ballmann C; Denney TS; Beyers RJ; Quindry T; Romero M; Amin R; Selsby JT; Quindry JC
Am J Physiol Heart Circ Physiol; 2017 Jan; 312(1):H128-H140. PubMed ID: 27836895
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
10. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
11. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
12. Similar efficacy from specific and non-specific mineralocorticoid receptor antagonist treatment of muscular dystrophy mice.
Lowe J; Floyd KT; Rastogi N; Schultz EJ; Chadwick JA; Swager SA; Zins JG; Kadakia FK; Smart S; Gomez-Sanchez EP; Gomez-Sanchez CE; Raman SV; Janssen PM; Rafael-Fortney JA
J Neuromuscul Dis; 2016; 3(3):395-404. PubMed ID: 27822449
[TBL] [Abstract][Full Text] [Related]
13. Complementary NAD
Frederick DW; McDougal AV; Semenas M; Vappiani J; Nuzzo A; Ulrich JC; Becherer JD; Preugschat F; Stewart EL; Sévin DC; Kramer HF
Skelet Muscle; 2020 Oct; 10(1):30. PubMed ID: 33092650
[TBL] [Abstract][Full Text] [Related]
14. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum brevis and interosseus muscles from the mdx mouse model of Duchenne muscular dystrophy.
Carberry S; Brinkmeier H; Zhang Y; Winkler CK; Ohlendieck K
Int J Mol Med; 2013 Sep; 32(3):544-56. PubMed ID: 23828267
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
16. Neopterin/7,8-dihydroneopterin is elevated in Duchenne muscular dystrophy patients and protects mdx skeletal muscle function.
Lindsay A; Schmiechen A; Chamberlain CM; Ervasti JM; Lowe DA
Exp Physiol; 2018 Jul; 103(7):995-1009. PubMed ID: 29791760
[TBL] [Abstract][Full Text] [Related]
17. The D2.mdx mouse as a preclinical model of the skeletal muscle pathology associated with Duchenne muscular dystrophy.
Hammers DW; Hart CC; Matheny MK; Wright LA; Armellini M; Barton ER; Sweeney HL
Sci Rep; 2020 Aug; 10(1):14070. PubMed ID: 32826942
[TBL] [Abstract][Full Text] [Related]
18. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy.
Dorchies OM; Wagner S; Vuadens O; Waldhauser K; Buetler TM; Kucera P; Ruegg UT
Am J Physiol Cell Physiol; 2006 Feb; 290(2):C616-25. PubMed ID: 16403950
[TBL] [Abstract][Full Text] [Related]
19. A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
Mele A; Mantuano P; De Bellis M; Rana F; Sanarica F; Conte E; Morgese MG; Bove M; Rolland JF; Capogrosso RF; Pierno S; Camerino GM; Trabace L; De Luca A
Transl Res; 2019 Feb; 204():82-99. PubMed ID: 30347179
[TBL] [Abstract][Full Text] [Related]
20. Effects of PDE5 inhibition on dystrophic muscle following an acute bout of downhill running and endurance training.
Batra A; Vohra RS; Chrzanowski SM; Hammers DW; Lott DJ; Vandenborne K; Walter GA; Forbes SC
J Appl Physiol (1985); 2019 Jun; 126(6):1737-1745. PubMed ID: 30946638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
